Ameliorative effects of probiotics in AlCl3-induced mouse model of Alzheimer's disease

Maryam Hamid1, Saadia Zahid2

  • 1Neurobiology Research Laboratory, Department of Healthcare Biotechnology, Atta ur Rahman School of Applied Biosciences, National University of Sciences and Technology (NUST), Islamabad, Pakistan.

Insights

This study shows that a combination of Lactobacillus rhamnosus GG and Bifidobacterium BB-12 probiotics can significantly reduce anxiety and improve memory in a mouse model of Alzheimer's disease (AD). These probiotics may offer a new therapeutic approach for AD by modulating the gut-brain axis.

Area of Science:

  • Neuroscience
  • Microbiology
  • Pharmacology

Background:

  • Gut microbiome alterations are increasingly linked to neurodegenerative disorders like Alzheimer's disease (AD).
  • The gut microbiota influences the gut-brain axis, impacting neurological functions and mood regulation.
  • Alzheimer's disease is characterized by cognitive deficits, anxiety, and neuroinflammation.

Purpose of the Study:

  • To investigate the therapeutic potential of combined probiotics, Lactobacillus rhamnosus GG (LGG®) and Bifidobacterium BB-12 (BB-12®), in an aluminum chloride (AlCl3)-induced AD mouse model.
  • To compare the effects of these probiotics with donepezil, a standard AD medication.
  • To evaluate the impact of probiotics on cognitive function, anxiety-like behavior, and neuroinflammation.

Main Methods:

  • Mice were induced with Alzheimer's disease using AlCl3 and treated with a combination of LGG® and BB-12® probiotics.
  • Behavioral assessments including Morris Water Maze, Novel Object Recognition, Elevated Plus Maze, and Y-maze were performed.
  • The expression levels of inflammatory cytokines (TNF-α and IL-1β) were analyzed.

Main Results:

  • Combined probiotic treatment significantly reduced anxiety-like behaviors in AlCl3-treated mice.
  • Probiotic administration markedly improved spatial and recognition memory compared to the AlCl3-only group.
  • Treatment with LGG® and BB-12® normalized the expression of key inflammatory cytokines, TNF-α and IL-1β.

Conclusions:

  • The combination of Lactobacillus rhamnosus GG and Bifidobacterium BB-12 demonstrates significant potential in ameliorating cognitive deficits and anxiety associated with Alzheimer's disease.
  • These probiotics may serve as a viable complementary therapy for AD by modulating the gut-brain axis and reducing neuroinflammation.
  • Further research into probiotic-based interventions for neurodegenerative diseases is warranted.